The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance

$71.00 plus tax (Refund Policy)

Buy Article:

Abstract:

CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize about 18% of currently available drugs. Some of the important groups of drugs that are metabolized by them are antihypertensives, hypoglycemics, anticonvulsants, antiulcer drugs etc. Genes encoding these enzymes are polymorphically expressed. Thirty variant alleles for CYP2C9 and 21 for CYP2C19 have been reported. The frequencies of these polymorphic alleles show marked inter-ethnic variation. Several reports have been published showing the clinical importance of this polymorphism. This review summarizes the currently available important information on this topic.





Keywords: Adverse Drug Reactions; CYP2C9 variant alleles; Hypoglycemic Agents; Inter-ethnic variation; Phenytoin; Warfarin

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/157488407779422302

Affiliations: Pharmacogenomics Laboratory,Department of Pharmacology, JIPMER, Pondicherry - 605006, India.

Publication date: January 1, 2007

More about this publication?
  • Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more